Absci appoints biopharma leader mary szela to board of directors

Vancouver, wash., july 07, 2025 (globe newswire) -- absci (nasdaq: absi), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative ai, today announced the appointment of veteran biopharmaceutical executive mary szela to its board of directors.
ABSI Ratings Summary
ABSI Quant Ranking